Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab.

PURPOSE The antiepidermal growth factor receptor (EGFR) antibody cetuximab shows activity in multiple epithelial tumor types; however, responses are seen in only a subset of patients. This study was conducted to identify markers that are associated with disease control in patients treated with cetuximab. PATIENTS AND METHODS One hundred ten patients with metastatic colorectal cancer were enrolled onto a cetuximab monotherapy trial. Transcriptional profiling was conducted on RNA from mandatory pretreatment metastatic biopsies to identify genes whose expression correlates with best clinical responses. EGFR and K-ras mutation analyses and EGFR gene copy number analyses were performed on DNA from pretreatment biopsies. RESULTS Gene expression profiles showed that patients with tumors that express high levels of the EGFR ligands epiregulin and amphiregulin are more likely to have disease control with cetuximab (EREG, P = .000015; AREG, P = .000025). Additionally, patients whose tumors do not have K-ras mutations have a significantly higher disease control rate than patients with K-ras mutations (P = .0003). Furthermore, patients with tumors that have high expression of EREG or AREG also have significantly longer progression-free survival (PFS) than patients with low expression (EREG: P = .0002, hazard ratio [HR] = 0.47, and median PFS, 103.5 v 57 days, respectively; AREG: P < .0001, HR = 0.44, and median PFS, 115.5 v 57 days, respectively). CONCLUSION Patients with tumors that have high gene expression levels of epiregulin and amphiregulin and patients with wild-type K-ras are more likely to have disease control on cetuximab treatment. The identified markers could be developed further to select patients for cetuximab therapy.

[1]  L. Schwartz,et al.  Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  L. Saltz Epidermal growth factor receptor-negative colorectal cancer: is there truly such an entity? , 2005, Clinical colorectal cancer.

[3]  Neal J Meropol,et al.  Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  M. Conti,et al.  Role of the Epidermal Growth Factor Network in Ovarian Follicles the Physiology of Follicle Maturation and Ovulation , 2022 .

[5]  J. Baselga,et al.  Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Silvia Benvenuti,et al.  Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. , 2005, The Lancet. Oncology.

[7]  H. Akgül,et al.  Activities of adenosine deaminase and 5′-nucleotidase in cancerous and noncancerous human colorectal tissues , 2000, Medical oncology.

[8]  E. Van Cutsem,et al.  Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Xia Han,et al.  Colorectal cancers with microsatellite instability display mRNA expression signatures characteristic of increased immunogenicity , 2004, Molecular Cancer.

[10]  Armando Santoro,et al.  Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. , 2004, The New England journal of medicine.

[11]  A. Lièvre,et al.  KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. , 2006, Cancer research.

[12]  R. Harris,et al.  Autocrine, paracrine and juxtacrine signaling by EGFR ligands. , 2005, Cellular signalling.

[13]  A. Miller,et al.  Reporting results of cancer treatment , 1981, Cancer.

[14]  Elisa Rossi,et al.  Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. , 2005, Journal of the National Cancer Institute.

[15]  Franco Mosca,et al.  Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. , 2006, Cancer research.

[16]  H. Varmus,et al.  KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib , 2005, PLoS medicine.

[17]  P. Jänne,et al.  Responsiveness to cetuximab without mutations in EGFR. , 2005, The New England journal of medicine.

[18]  N. Normanno,et al.  Epidermal growth factor receptor (EGFR) signaling in cancer. , 2006, Gene.

[19]  N. Meropol Epidermal growth factor receptor inhibitors in colorectal cancer: it's time to get back on target. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Y. Yarden,et al.  Epiregulin Is a Potent Pan-ErbB Ligand That Preferentially Activates Heterodimeric Receptor Complexes* , 1998, The Journal of Biological Chemistry.

[21]  P. Jänne,et al.  Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Z. Ronai,et al.  K-ras mutation: early detection in molecular diagnosis and risk assessment of colorectal, pancreas, and lung cancers--a review. , 2000, Cancer detection and prevention.

[23]  E. Van Cutsem,et al.  Activity of cetuximab in patients with colorectal cancer refractory to both irinotecan and oxaliplatin. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.